Overview
Paysign Q3 revenue grows 41.6% yr/yr, beating analyst expectations
Adjusted EBITDA for Q3 beats consensus, reflecting improved operational efficiency
Pharma patient affordability revenue grows 141.9%, driving overall revenue growth
Outlook
Paysign expects full-year 2025 revenue between $80.5 mln and $81.5 mln
Company anticipates flat plasma revenue in Q4 2025
Paysign projects full-year 2025 Adjusted EBITDA between $19 mln and $20 mln
Result Drivers
PHARMA REVENUE GROWTH - Pharma patient affordability revenue increased 141.9% yr/yr, driven by 39 net new programs and increased fees
PLASMA REVENUE GROWTH - Plasma revenue increased 12.4% yr/yr, supported by 117 net new plasma centers despite lower average revenue per center
SERVICE EXPANSION - New customer service contact center expanded support capacity fourfold, aiding in meeting surging demand
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $21.60 mln | $19.92 mln (5 Analysts) |
Q3 EPS | $0.04 | ||
Q3 Net Income | $2.22 mln | ||
Q3 Adjusted EBITDA | Beat | $5.04 mln | $4.60 mln (5 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy"
Wall Street's median 12-month price target for Paysign Inc is $9.00, about 42.7% above its November 11 closing price of $5.16
The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 47 three months ago
Press Release: ID:nBw2WHj83a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)